- Home
- PLX vs CEV Comparison
PLX vs CEV Comparison
Compare PLX & CEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- CEV
- Stock Information
- Founded
- PLX 1993
- CEV 1999
- Country
- PLX Israel
- CEV United States
- Employees
- PLX N/A
- CEV N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- CEV Finance/Investors Services
- Sector
- PLX Health Care
- CEV Finance
- Exchange
- PLX Nasdaq
- CEV Nasdaq
- Market Cap
- PLX 79.4M
- CEV 75.9M
- IPO Year
- PLX 1998
- CEV N/A
- Fundamental
- Price
- PLX $1.68
- CEV $10.40
- Analyst Decision
- PLX
- CEV
- Analyst Count
- PLX 0
- CEV 0
- Target Price
- PLX N/A
- CEV N/A
- AVG Volume (30 Days)
- PLX 439.0K
- CEV 19.6K
- Earning Date
- PLX 11-14-2024
- CEV 01-01-0001
- Dividend Yield
- PLX N/A
- CEV 4.23%
- EPS Growth
- PLX N/A
- CEV N/A
- EPS
- PLX N/A
- CEV 0.36
- Revenue
- PLX $45,667,000.00
- CEV N/A
- Revenue This Year
- PLX N/A
- CEV N/A
- Revenue Next Year
- PLX $88.94
- CEV N/A
- P/E Ratio
- PLX N/A
- CEV $29.36
- Revenue Growth
- PLX N/A
- CEV N/A
- 52 Week Low
- PLX $0.82
- CEV $8.83
- 52 Week High
- PLX $1.90
- CEV $10.91
- Technical
- Relative Strength Index (RSI)
- PLX 74.56
- CEV 39.01
- Support Level
- PLX $1.14
- CEV $10.36
- Resistance Level
- PLX $1.75
- CEV $10.44
- Average True Range (ATR)
- PLX 0.12
- CEV 0.08
- MACD
- PLX 0.05
- CEV 0.00
- Stochastic Oscillator
- PLX 87.29
- CEV 18.18
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.